Literature DB >> 14506150

Clinical significance of CCR4 expression in adult T-cell leukemia/lymphoma: its close association with skin involvement and unfavorable outcome.

Takashi Ishida1, Atae Utsunomiya, Shinsuke Iida, Hiroshi Inagaki, Yoshifusa Takatsuka, Shigeru Kusumoto, Genji Takeuchi, Shigeki Shimizu, Masato Ito, Hirokazu Komatsu, Atsushi Wakita, Tadaaki Eimoto, Kouji Matsushima, Ryuzo Ueda.   

Abstract

Adult T-cell leukemia/lymphoma (ATLL) is a distinct clinical entity among mature T-cell neoplasms, and its causative agent has been confirmed to be long-term infection by human T-lymphotropic virus type 1. A recent study demonstrated frequent expression of a chemokine receptor, CC chemokine receptor (CCR)4, which is known as a Th2 marker but not CXC chemokine receptor (CXCR)3, which is known as a Th1 marker, among both ATLL- and human T-lymphotropic virus type 1-immortalized T cells. In this study, immunostaining analysis for CCR4 and CXCR3 expression in ATLL cells obtained from 103 patients with ATLL was performed, and the clinical parameters and overall survival of the CCR4-positive and -negative cases were compared. Ninety-one (88.3%) of the 103 cases were positive for CCR4 staining, whereas only 5 (4.9%) were positive for CXCR3 staining. Positivity for CCR4 was significantly associated with skin involvement (P < 0.05), although there were no significant differences in clinical characteristics between the CCR4-positive and -negative cases at the time of initial diagnosis. CCR4(+) ATLL cells may accumulate in the skin because of the expression of a CCR4 ligand, thymus and activation-regulated chemokine (TARC), on normal and inflamed cutaneous endothelia. As for survival analysis, positivity for CCR4 expression was extracted as an unfavorable prognostic factor as well as other factors, including the presence of B symptoms and extranodal involvement of more than one site. Multivariate analysis confirmed that CCR4 expression was an independent and significant prognostic factor (P < 0.05). Thus, our finding may provide a novel insight into not only the biological but also the clinical features of ATLL.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14506150

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  106 in total

Review 1.  Therapeutic antibodies directed at G protein-coupled receptors.

Authors:  Catherine J Hutchings; Markus Koglin; Fiona H Marshall
Journal:  MAbs       Date:  2010-11-01       Impact factor: 5.857

Review 2.  Mature T-cell leukemias: Molecular and Clinical Aspects.

Authors:  Nathanael G Bailey; Kojo S J Elenitoba-Johnson
Journal:  Curr Hematol Malig Rep       Date:  2015-12       Impact factor: 3.952

3.  EPOCH regimen as salvage therapy for adult T-cell leukemia-lymphoma.

Authors:  Eo Toriyama; Yoshitaka Imaizumi; Hiroaki Taniguchi; Jun Taguchi; Jun Nakashima; Hidehiro Itonaga; Shinya Sato; Koji Ando; Yasushi Sawayama; Tomoko Hata; Takuya Fukushima; Yasushi Miyazaki
Journal:  Int J Hematol       Date:  2018-04-12       Impact factor: 2.490

4.  Breast cancer lung metastasis requires expression of chemokine receptor CCR4 and regulatory T cells.

Authors:  Purevdorj B Olkhanud; Dolgor Baatar; Monica Bodogai; Fran Hakim; Ronald Gress; Robin L Anderson; Jie Deng; Mai Xu; Susanne Briest; Arya Biragyn
Journal:  Cancer Res       Date:  2009-06-30       Impact factor: 12.701

5.  Anti-CCR4 mAb selectively depletes effector-type FoxP3+CD4+ regulatory T cells, evoking antitumor immune responses in humans.

Authors:  Daisuke Sugiyama; Hiroyoshi Nishikawa; Yuka Maeda; Megumi Nishioka; Atsushi Tanemura; Ichiro Katayama; Sachiko Ezoe; Yuzuru Kanakura; Eiichi Sato; Yasuo Fukumori; Julia Karbach; Elke Jäger; Shimon Sakaguchi
Journal:  Proc Natl Acad Sci U S A       Date:  2013-10-14       Impact factor: 11.205

6.  Linkage of expression of chemokine receptors (CXCR3 and CCR4) and cytotoxic molecules in peripheral T cell lymphoma, not otherwise specified and ALK-negative anaplastic large cell lymphoma.

Authors:  Naoko Asano; Ritsuro Suzuki; Koichi Ohshima; Yoshitoyo Kagami; Fumihiro Ishida; Tadashi Yoshino; Hiroshi Ogawa; Yasuo Morishima; Shigeo Nakamura
Journal:  Int J Hematol       Date:  2010-03-09       Impact factor: 2.490

7.  Selective Expression of CCR10 and CXCR3 by Circulating Human Herpes Simplex Virus-Specific CD8 T Cells.

Authors:  Michael T Hensel; Tao Peng; Anqi Cheng; Stephen C De Rosa; Anna Wald; Kerry J Laing; Lichen Jing; Lichun Dong; Amalia S Magaret; David M Koelle
Journal:  J Virol       Date:  2017-09-12       Impact factor: 5.103

Review 8.  Dysregulation of microRNAs and their association in the pathogenesis of T-cell lymphoma/leukemias.

Authors:  Sho Ikeda; Hiroyuki Tagawa
Journal:  Int J Hematol       Date:  2014-02-25       Impact factor: 2.490

9.  Clinical factors to predict outcome following mogamulizumab in adult T-cell leukemia-lymphoma.

Authors:  Jun Nakashima; Yoshitaka Imaizumi; Hiroaki Taniguchi; Koji Ando; Masako Iwanaga; Hidehiro Itonaga; Shinya Sato; Yasuhi Sawayama; Tomoko Hata; Shinichiro Yoshida; Yukiyoshi Moriuchi; Yasushi Miyazaki
Journal:  Int J Hematol       Date:  2018-07-21       Impact factor: 2.490

Review 10.  Advances in targeted therapy for malignant lymphoma.

Authors:  Li Wang; Wei Qin; Yu-Jia Huo; Xiao Li; Qing Shi; John E J Rasko; Anne Janin; Wei-Li Zhao
Journal:  Signal Transduct Target Ther       Date:  2020-03-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.